Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder

The European Commission decision is expected within 67 days of the CHMP opinion Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative

Related Keywords

Norway ,Finland ,Liechtenstein ,Iceland ,Helsinki ,Eteläuomen Läi ,Finnish ,Scott Braunstein ,Sasha Damouni Ellis ,Gewinn Nur ,Marinus Pharmaceuticals ,European Union ,Committee For Medicinal Products Human Use ,Corporate Affairs Investor Relations ,Exchange Commission ,Nasdaq ,European Medicines Agency ,Orion Corporation ,European Commission ,Marinus Pharmaceuticals Inc ,Medicinal Products ,Human Use ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Lancet Neurology ,Damouni Ellis ,Vice President ,Marinus ,Pharmaceuticals ,Eceives ,Positive ,Thmp ,Opinion ,Talmy ,Anaxolone ,Adjunctive ,Treatment ,Seizures ,Ssociated ,Ith ,Cdkl5 ,Deficiency ,Disorder ,